FDA approves new breast cancer treatment for patients with a specific genetic mutation

Author(s):

fda breast cancer treatment patient genetic mutation

On Jan. 12, the U.S. Food and Drug Administration (FDA) expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have metastasized and whose tumors have the BRCA gene mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here